Johnson & Johnson has paused all U.S. Varipulse cases as it investigates four reported neurovascular events.
In a pivotal study, three of 277 patients (1.1%) had cerebrovascular events (two strokes and one transient ischemic attack).

Announcing major milestones for the company’s suite of pulse field ablation (PFA) devices in electrophysiology, Abbott Laboratories said it is advancing treatment for patients with abnormal heart rhythms like atrial fibrillation (AFib).